Breaking News, Collaborations & Alliances

Genmab, CureVac Enter Strategic Antibody Alliance

Collaboration will leverage CureVac’s mRNA technology and Genmab’s antibody technologies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab and CureVac AG have entered into a research collaboration and license agreement for the research and development of differentiated mRNA-based antibody products by combining CureVac’s mRNA technology with Genmab’s antibody technologies. Genmab will provide CureVac with $10 million upfront and will make a €20 million equity investment in CureVac. The companies will collaborate to identify an initial product candidate and CureVac will contribute a portion of the overall costs for the deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters